IPO Guru
Dilip Davda

Dilip Davda

๐Ÿ… Ranked #36 on IPO Guru
SEBI Registered RA ยท INH000003127

Dilip Davda is a veteran financial journalist and SEBI-registered Research Analyst with over four decades of experience in the Indian capital markets. Based in Maharashtra, he has been a prominent voice in the industry since 1978, specializing in the primary market with a heavy focus on SME IPOs and NCD reviews.

12 Mainboard 1 SME

Total Reviews

13

All time

Apply Rate

8%

of all calls

Win Rate

100%

Apply calls with +ve listing

Avg Listing Gain

+20.1%

on apply/may apply calls

Avg Total Gain

+42.4%

on apply/may apply calls

๐Ÿ†•
๐Ÿ†• Early Track Record

Performance Dashboard

Less than 5 reviews in last 12 months. Not enough data to rank yet.

Based on 1 reviews in the last 12 months.

How is this calculated?

Accuracy

0%

Return Quality

0%

Consistency

0%

Horizon

0%

โš ๏ธ Disclaimer: Past results are not guaranteed for future. This score reflects the last 1 year only. Use for research purposes only.

Verdict Breakdown (All Time)

Apply 1 (100%)
Corona Remedies

๐Ÿ† Best Call

Corona Remedies

Verdict: Not rated

+38.4%

Listing gain

Shree Ram Twistex

๐Ÿ“‰ Worst Call

Shree Ram Twistex

Verdict: Not Rated

-34.6%

Listing gain

Review History

Track record of Dilip Davda

IPO Name Verdict Total Gain Report
Shree Ram Twistex
Shree Ram Twistex
Not Rated -57.9% PDF
Marushika Technology
Marushika Technology
Not Rated -23.1% PDF
Shadowfax Technologies
Shadowfax Technologies
Not rated +55.0% โ€”
Amagi Media Labs
Amagi Media Labs
Not rated +15.0% โ€”
Gujarat Kidney & Super Speciality
Gujarat Kidney & Super Speciality
Not rated +24.6% โ€”
KSH International
KSH International
Not rated +63.0% โ€”
ICICI Prudential AMC
ICICI Prudential AMC
Apply +42.4% โ€”
Nephrocare Health Services
Nephrocare Health Services
Not rated +35.1% โ€”
Park Medi World
Park Medi World
Not rated +57.2% โ€”
Corona Remedies
Corona Remedies
Not rated +70.2% โ€”
Wakefit Innovations
Wakefit Innovations
Not rated -27.6% โ€”
Meesho
Meesho
Not rated +75.8% โ€”
Aequs
Aequs
Not rated +58.8% โ€”

Frequently Asked Questions

Is Dilip Davda SEBI registered?

Yes, Dilip Davda is a SEBI registered Research Analyst (Registration No. INH000003127). SEBI registration means the analyst is regulated by the Securities and Exchange Board of India and authorised to publish investment research.

How many IPO reviews has Dilip Davda given?

Dilip Davda has reviewed 13 IPOs in total, covering 12 Mainboard and 1 SME IPOs. The apply rate across all calls is 8%.

What is Dilip Davda's IPO recommendation win rate?

Dilip Davda has a 100% win rate โ€” 100% of their Apply calls resulted in a positive listing gain on the NSE/BSE. The average listing gain on Apply calls is +20.1%.

Where can I read Dilip Davda's IPO recommendations?

All IPO reviews by Dilip Davda are listed on this page. You can filter by the last 12 months or all-time, and view the verdict (Apply / May Apply / Neutral / Avoid) alongside the actual listing and current gains for each IPO.